Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan

Advances in Experimental Medicine and Biology

Volumn 467, Issue , 2000, Pages 461-468

  Klarskov, K ^a   Johnson, K L ^a   Benson, L M ^a   Gleich, G J ^a   Naylor, S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; TRYPTOPHAN;

CONFERENCE PAPER; DEPRESSION; DIET SUPPLEMENTATION; DRUG CONTAMINATION; EOSINOPHILIA MYALGIA SYNDROME; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSOMNIA; MASS SPECTROMETRY; MOLECULAR WEIGHT; OBESITY; PRIORITY JOURNAL;

5-HYDROXYTRYPTOPHAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETARY SUPPLEMENTS; DRUG CONTAMINATION; EOSINOPHILIA-MYALGIA SYNDROME; HUMANS; MASS SPECTROMETRY; REPRODUCIBILITY OF RESULTS;

EID: 0034468892     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (9)

1. Alternative medicine-the risks of untested and unregulated remedies
2. L-tryptophan and eosinophilia-myalgia syndrome in New Mexico
3. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan
4. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan
5. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa
6. Eosinophilia-myalgia syndrome: Mortality data from the US national surveillance system
7. Problems with off-the-shelf 5-hydroxy-L-tryptophan